These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2476106)

  • 1. Study of nafenopin, a hypolipidemic drug on liver metabolism.
    Gerbracht U; Köpf G; Wüst G; Weisse G; Schlatterer B; Eigenbrodt E
    Arch Toxicol Suppl; 1989; 13():304-8. PubMed ID: 2476106
    [No Abstract]   [Full Text] [Related]  

  • 2. Microbody proliferation in liver induced by nafenopin, a new hypolipidemic drug: comparison with CPIB.
    Reddy J; Svoboda D; Azarnoff D
    Biochem Biophys Res Commun; 1973 May; 52(2):537-43. PubMed ID: 4711169
    [No Abstract]   [Full Text] [Related]  

  • 3. Nafenopin-induced hepatic microbody (peroxisome) proliferation and catalase synthesis in rats and mice. Absence of sex difference in response.
    Reddy JK; Azarnoff DL; Svoboda DJ; Prasad JD
    J Cell Biol; 1974 May; 61(2):344-58. PubMed ID: 4208071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased hepatotoxicity of carbon tetrachloride by the hypolipidemic drug nafenopin in rats.
    Charpentier D; Tuchweber B
    Res Commun Chem Pathol Pharmacol; 1982 Jun; 36(3):449-61. PubMed ID: 6289397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clofibrate and nafenopin (SU-13437): effects on plasma clearance and tissue distribution of chylomicron triglyceride in the dog.
    Cenedella RJ
    Lipids; 1972 Oct; 7(10):644-52. PubMed ID: 4635558
    [No Abstract]   [Full Text] [Related]  

  • 6. Mitogenic effect in mouse liver induced by a hypolipidemic drug, nafenopin.
    Moody DE; Rao MS; Reddy JK
    Virchows Arch B Cell Pathol; 1977 Apr; 23(4):291-6. PubMed ID: 404752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug metabolism and morphologic changes in the liver of nafenopin-treated rats.
    Tuchweber B; Kourounakis P; Latour JG
    Arch Int Pharmacodyn Ther; 1976 Aug; 222(2):309-21. PubMed ID: 984981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hypolipidemic drugs, nafenopin and clofibrate, on the concentration of ligandin and Z protein in rat liver.
    Fleischner G; Meijer DK; Levine WG; Gatmaitan Z; Gluck R; Arias IM
    Biochem Biophys Res Commun; 1975 Dec; 67(4):1401-7. PubMed ID: 812503
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of nafenopin (SU-13,437) on liver functions. Hepatic uptake and biliary excretion of ouabain in the rat.
    Meijer DK; Bognacki J; Levine WG
    Drug Metab Dispos; 1975; 3(3):220-5. PubMed ID: 238821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased plasma clearance rate of thyroxine despite decreased 5'-monodeiodination: study with a peroxisome proliferator in the rat.
    Kaiser CA; Seydoux J; Giacobino JP; Girardier L; Burger AG
    Endocrinology; 1988 Mar; 122(3):1087-93. PubMed ID: 3342745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of three hypolipidemic drugs on catalase activity and peroxisomal and mitochondrial palmitate oxidation in rat cardiac and skeletal muscle.
    MacDonald RS; Swan PB
    Biochim Biophys Acta; 1986 Feb; 880(2-3):153-60. PubMed ID: 3942787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of CeCl3-induced hepatotoxicity by hypolipidemic compounds.
    Tuchweber B; Salas M
    Arch Toxicol; 1978 Dec; 41(3):223-32. PubMed ID: 736793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea pig, and marmoset.
    Lake BG; Evans JG; Gray TJ; Körösi SA; North CJ
    Toxicol Appl Pharmacol; 1989 Jun; 99(1):148-60. PubMed ID: 2499080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of various hypolipidemic drugs on fatty acid composition of liver and serum lipids.
    Maier R; Muller K
    Adv Exp Med Biol; 1975; 63():349-57. PubMed ID: 1199873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of hypolipidemic drugs nafenopin and clofibrate on phenotypic expression and cell death (apoptosis) in altered foci of rat liver.
    Gerbracht U; Bursch W; Kraus P; Putz B; Reinacher M; Timmermann-Trosiener I; Schulte-Hermann R
    Carcinogenesis; 1990 Apr; 11(4):617-24. PubMed ID: 1691053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator nafenopin potentiated cytotoxicity and genotoxicity of cyclophosphamide in the liver and bone marrow cells.
    Voskoboinik I; Drew R; Ahokas JT
    Chem Biol Interact; 1997 Jul; 105(2):81-97. PubMed ID: 9251722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two hypolipidemic peroxisome proliferators increase the number of lamellar bodies in alveolar cells type II of the rat lung.
    Fringes B; Reith A
    Exp Mol Pathol; 1988 Apr; 48(2):262-71. PubMed ID: 3258252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase in hepatic carnitine acetyltransferase activity associated with peroxisomal (microbody) proliferation induced by the hypolipidemic drugs clofibrate, nafenopin, and methyl clofenapate.
    Moody DE; Reddy JK
    Res Commun Chem Pathol Pharmacol; 1974 Nov; 9(3):501-10. PubMed ID: 4445568
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of nafenopin on the uptake of bilirubin and sulfobromophthalein by isolated perfused rat liver.
    Gärtner U; Stockert RJ; Levine WG; Wolkoff AW
    Gastroenterology; 1982 Dec; 83(6):1163-9. PubMed ID: 6751925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of cytosolic and microsomal epoxide hydrolases by the hypolipidaemic compound nafenopin in the mouse liver.
    Waechter F; Bieri F; Stäubli W; Bentley P
    Biochem Pharmacol; 1984 Jan; 33(1):31-4. PubMed ID: 6704141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.